Financial Results for the Quarter ended 31st December, 2025 and Approval of Postal Ballot Notice
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vaishali Pharma reported Q3 FY26 standalone revenue of ₹24.65 crore, down about 12% year-on-year from ₹27.91 crore, with profit after tax falling to ₹1.30 crore from ₹1.44 crore. For the nine-month period, revenue grew roughly 18.7% to ₹81.85 crore, but profit after tax declined about 26% to ₹3.77 crore versus ₹5.11 crore last year, indicating margin compression. The statutory auditor issued an unmodified limited review report on both standalone and consolidated results. The Board also approved a preferential issue of up to 61.23 lakh equity shares at ₹20 each (aggregating ~₹12.25 crore) to Kesar Pharma Limited, its associate company, entirely through a share-swap route to acquire further equity in Kesar Pharma. This will dilute existing shareholders by about 4.48% on a post-issue basis and is subject to shareholder approval via postal ballot.
Near-term pressure on the stock is possible given the year-on-year decline in Q3 revenue and PAT, along with the 26% drop in nine-month profits despite revenue growth. The share-swap acquisition strengthens the company's stake in its associate Kesar Pharma without cash outflow, but introduces a related-party transaction and ~4.5% equity dilution that shareholders must approve.